{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:42:19Z","timestamp":1791567739955,"version":"4.3.4"},"reference-count":16,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background\u2003Acquired hemophilia A (AHA) is a severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). Standard treatment consists of bleeding control with bypassing agents and immunosuppressive therapy. Emicizumab is a bispecific antibody that mimics the function of activated FVIII irrespective of the presence of neutralizing antibodies. Recently, the GTH-AHA-EMI study demonstrated that emicizumab prevents bleeds and allows to postpone immunosuppression, which may influence future treatment strategies.<\/jats:p>\n                  <jats:p>Aim\u2003To provide clinical practice recommendations on the use of emicizumab in AHA.<\/jats:p>\n                  <jats:p>Methods\u2003A Delphi procedure was conducted among 33 experts from 16 German and Austrian hemophilia care centers. Statements were scored on a scale of 1 to 9, and agreement was defined as a score of \u22657. Consensus was defined as \u226575% agreement among participants, and strong consensus as \u226595% agreement.<\/jats:p>\n                  <jats:p>Results\u2003Strong consensus was reached that emicizumab is effective for bleed prophylaxis and should be considered from the time of diagnosis (100% consensus). A fast-loading regimen of 6\u2009mg\/kg on day 1 and 3\u2009mg\/kg on day 2 should be used if rapid bleeding prophylaxis is required (94%). Maintenance doses of 1.5\u2009mg\/kg once weekly should be given (91%). Immunosuppression should be offered to patients on emicizumab if they are eligible based on physical status (97%). Emicizumab should be discontinued when remission of AHA is achieved (97%).<\/jats:p>\n                  <jats:p>Conclusion\u2003These GTH consensus recommendations provide guidance to physicians on the use of emicizumab in AHA and follow the results of clinical trials that have shown emicizumab is effective in preventing bleeding in AHA.<\/jats:p>","DOI":"10.1055\/a-2197-9738","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T19:35:32Z","timestamp":1701718532000},"page":"466-471","source":"Crossref","is-referenced-by-count":28,"title":["Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group"],"prefix":"10.1055","volume":"44","author":[{"given":"Christian","family":"Pfrepper","sequence":"additional","affiliation":[{"name":"Division of Hemostaseology, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klamroth","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Vascular Medicine and Coagulation Disorders, Vivantes Clinic Friedrichshain, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Holstein","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Eichler","sequence":"additional","affiliation":[{"name":"Clinical Hemostaseology and Transfusion Medicine, Saarland University Hospital, Homburg\/Saar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Hart","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Moehnle","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Cell Therapeutics and Hemostaseology, University Hospital, Ludwig Maximilian University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Schilling","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Trautmann-Grill","sequence":"additional","affiliation":[{"name":"Medical Clinic I, University Hospital Carl Gustav Carus, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alrifai","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Hemostasis, University Hospital Giessen and Marburg GmbH, Giessen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[{"name":"Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[{"name":"Medical Clinic II, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Knoebl","sequence":"additional","affiliation":[{"name":"Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Tiede","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"issue":"07","key":"ref1","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"A Tiede","year":"2020","journal-title":"Haematologica"},{"issue":"03","key":"ref2","first-page":"279","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"136","author":"K Holstein","year":"2020","journal-title":"Blood"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"F Baudo","year":"2012","journal-title":"Blood"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"R Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/hae.13844","article-title":"Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: a global expert consensus statement","volume":"25","author":"A Tiede","year":"2019","journal-title":"Haemophilia"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"P Collins","year":"2012","journal-title":"Blood"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"A Tiede","year":"2015","journal-title":"Blood"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/hae.12138","article-title":"Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'H\u00e9mophilie Acquise) registry","volume":"19","author":"J Y Borg","year":"2013","journal-title":"Haemophilia"},{"issue":"09","key":"ref9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"09","key":"ref10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"J Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"C N\u00e9grier","year":"2023","journal-title":"Lancet Haematol"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hae.14450","article-title":"Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature","volume":"28","author":"V M Thomas","year":"2022","journal-title":"Haemophilia"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"P Knoebl","year":"2021","journal-title":"Blood"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"M Shima","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/hae.14707","article-title":"Effectiveness of monthly low dose emicizumab prophylaxis without 4-week loading doses among patients with haemophilia A with and without inhibitors: A case series report","volume":"29","author":"A Chuansumrit","year":"2022","journal-title":"Haemophilia"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/hae.14785","article-title":"Low dose emicizumab prophylaxis in haemophilia a patients: a pilot study from India","volume":"29","author":"S Bansal","year":"2023","journal-title":"Haemophilia"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2197-9738.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T18:31:30Z","timestamp":1733855490000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2197-9738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":16,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2024,12,10]]},"published-print":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2197-9738","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]}}}